Acer Medical

Acer Medical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Acer Medical (6857.TWO) as of Nov 21, 2026 is 86.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 75.64 % — a change of 14.56% (higher).

FCF Conversion

86.66 %

YoY

14.56%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Acer Medical is 2025 86.66 % . FCF Conversion Rate (FCF/EBITDA) of Acer Medical was 2024 75.64 % . It decreases by 14.56% higher compared to the previous year.

The Acer Medical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
49.58 TWD
Jan 1, 2020
30.24 TWD
Jan 1, 2021
96.26 TWD
Jan 1, 2022
97.20 TWD
Jan 1, 2023
141.15 TWD
Jan 1, 2024
75.64 TWD
Jan 1, 2025
86.66 TWD
The Acer Medical FCF Conversion history
YEARFCF ConversionYoY
86.66 %+14.56%
75.64 %-46.41%
141.15 %+45.22%
97.20 %+0.97%
96.26 %+218.34%
30.24 %-39.01%
49.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acer Medical Stock analysis

What does Acer Medical do? Acer Medical, Inc. generates revenue through its AI medical diagnostic software and telemedicine solutions. The company's Artificial Intelligence Medical Diagnostic Software helps medical professionals make accurate and rapid diagnoses, while Telemedicine Solutions include telepresence clinics for home and facility consultations on chronic or non-emergency conditions, and telecare sites for specialist consultations at health clinics. Domestic and overseas markets are the primary sales segments, with products sold to medical facilities and other medical industries. The firm's main products are the AI diagnostic software and telemedicine services, targeting medical professionals and healthcare institutions. Sales are split between domestic and foreign markets, with telepresence clinics and telecare sites serving as key service offerings. Medical facilities and medical industries are the primary buyers of these solutions. Acer Medical, Inc. focuses on providing AI-driven diagnostic tools and telemedicine platforms to enhance medical care efficiency. Its domestic market segment serves local healthcare providers, while international markets expand its reach to global medical institutions seeking advanced diagnostic and telehealth services. Acer Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acer Medical stock

FCF Conversion Rate (FCF/EBITDA) of Acer Medical is 86.66 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Acer Medical changed from 75.64 % to 86.66 %, representing a 14.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Acer Medical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Acer Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Acer Medical

All Key Metrics — Acer Medical